Skip to content

Gwen Nichols speaks with Saad Usmani on CAR-T therapy advances
Study identifies nonmutational p53 dysfunction as MDS risk factor
FDA grants Orphan Drug designation for bexmarilimab in MDS
Triplet combination does not extend survival for patients with AML
Novel cell therapy approach shows ‘preliminary’ safety and efficacy in lymphoma

Join SOHO

Follow Us :

Insider Podcast
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Study identifies nonmutational p53 dysfunction as MDS risk factor

Cellular Therapy

Study identifies nonmutational p53 dysfunction as MDS risk factor

Leukemia

Study identifies nonmutational p53 dysfunction as MDS risk factor

Lymphoma

Study identifies nonmutational p53 dysfunction as MDS risk factor

Multiple Myeloma

Study identifies nonmutational p53 dysfunction as MDS risk factor

Myelodysplastic Syndromes

Study identifies nonmutational p53 dysfunction as MDS risk factor

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

May 14, 2025

Insider Podcast
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
Subscribe

SOHO Insider Hem/Onc Library Myelodysplastic Syndromes

MDS News

Organization structure, social network and teamwork concept on dark background. Business people icon on wooden cube blocks connecting network of connections.

Myelodysplastic Syndromes

Study identifies nonmutational p53 dysfunction as MDS risk factor

by Leah Sherwood
May 13, 2025
0 Comments

Green light

Myelodysplastic Syndromes

FDA grants Orphan Drug designation for bexmarilimab in MDS

by SOHO Insider Editors
May 12, 2025
0 Comments

European Commission

Myelodysplastic Syndromes

EC approves imetelstat for transfusion-dependent anemia in lower-risk MDS

by Leah Sherwood
March 17, 2025
0 Comments

Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms News Society Updates

Abstract submissions now open for SOHO 2025

by Leah Sherwood
February 14, 2025
0 Comments

Leukemia Myelodysplastic Syndromes News

Is unrelated cord blood better than bone marrow in haploidentical transplantation?

by SOHO Insider Editors
February 4, 2025
0 Comments

Myelodysplastic Syndromes

Dr. Garcia-Manero discusses mature data on luspatercept’s efficacy in MDS

by Leah Sherwood
January 22, 2025
0 Comments

fast track

Leukemia Acute Myeloid Leukemia Myelodysplastic Syndromes News

FDA grants fast track designation to LYT-200 in AML

by Leah Sherwood
January 17, 2025
0 Comments

Green light

Leukemia Myelodysplastic Syndromes

FDA approves imatinib oral solution to treat leukemia, other cancers

by Leah Sherwood
January 4, 2025
0 Comments

MyeloMatch, NCI

Leukemia Acute Myeloid Leukemia Myelodysplastic Syndromes

NCI’s myeloMATCH pushes the envelope in myeloid leukemia care

by Leah Sherwood
January 3, 2025
0 Comments

European Medicines Agency (EMA)

Myelodysplastic Syndromes News

CHMP announces positive opinion for imetelstat in lower-risk MDS treatment

by SOHO Insider Editors
December 19, 2024
0 Comments

1
2

Top Categories

Cellular Therapy

11

Leukemia

35

Lymphoma

34

Multiple Myeloma

27

Myelodysplastic Syndromes

13

Myeloproliferative Neoplasms

8

POPULAR NEWS

SOHO_Insider_Podcast-01[67]

Podcast

Gwen Nichols speaks with Saad Usmani on CAR-T therapy advances

May 14, 2025

Organization structure, social network and teamwork concept on dark background. Business people icon on wooden cube blocks connecting network of connections.

Myelodysplastic Syndromes

Study identifies nonmutational p53 dysfunction as MDS risk factor

May 13, 2025

Green light

Myelodysplastic Syndromes

FDA grants Orphan Drug designation for bexmarilimab in MDS

May 12, 2025

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Categories

Study identifies nonmutational p53 dysfunction as MDS risk factor

Cellular Therapy

Study identifies nonmutational p53 dysfunction as MDS risk factor

Leukemia

Study identifies nonmutational p53 dysfunction as MDS risk factor

Lymphoma

Study identifies nonmutational p53 dysfunction as MDS risk factor

Multiple Myeloma

Study identifies nonmutational p53 dysfunction as MDS risk factor

Myelodysplastic Syndromes

Study identifies nonmutational p53 dysfunction as MDS risk factor

Myeloproliferative Neoplasms

Subscribe

Recent Posts

SOHO_Insider_Podcast-01[67]

Gwen Nichols speaks with Saad Usmani on CAR-T therapy advances

Organization structure, social network and teamwork concept on dark background. Business people icon on wooden cube blocks connecting network of connections.

Study identifies nonmutational p53 dysfunction as MDS risk factor

Green light

FDA grants Orphan Drug designation for bexmarilimab in MDS

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.